Pharma: Astra Zeneca erwägt offenbar 400-Milliarden-Dollar-Fusion mit US-Rivalen Bristol Myers Squibb
Es wäre eine der größten Fusionen in der Wirtschaftsgeschichte. Laut einem Medienbericht wurden entsprechende Gespräche geführt. Ob es zu einem Zusammenschluss kommt ist jedoch noch offen.
Astra Zeneca and US rival Bristol Myers Squibb are reportedly in discussions about a potential merger, according to insiders. This could result in a combined company valued at nearly $400 billion, or around €345 billion, according to a Reuters source on Monday. The longevity of these talks remains uncertain. Astra Zeneca declined to comment, while Bristol Myers Squibb has not yet been reached for a statement.
A final decision may face significant antitrust hurdles. The insider suggests there are concerns about how US competition authorities under President Donald Trump's administration would assess the transaction. Trump emphasizes domestic investments and expanding US production. The merger would effectively involve a British firm taking over a major US pharmaceutical company.
Additionally, the portfolios of both companies overlap heavily: both Astra Zeneca and Bristol Myers Squibb generate the bulk of their revenue from cancer drugs, some of which directly compete with each other.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
